@article{d351b8f66f9046ee88381d2b9f909522,
title = "Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study",
abstract = "We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.",
keywords = "Adult, Aged, Antineoplastic Agents, Asia, Carcinoma, Hepatocellular, Disease Progression, Drug Administration Schedule, Europe, Female, Hepatocellular carcinoma, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridines, Receptor kinase inhibition, Regorafenib, Safety, Second line, Time Factors, Tolerability, Treatment Outcome, Adult, Aged, Antineoplastic Agents, Asia, Carcinoma, Hepatocellular, Disease Progression, Drug Administration Schedule, Europe, Female, Hepatocellular carcinoma, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridines, Receptor kinase inhibition, Regorafenib, Safety, Second line, Time Factors, Tolerability, Treatment Outcome",
author = "Jordi Bruix and Won-Young Tak and Antonio Gasbarrini and Armando Santoro and Massimo Colombo and Ho-Yeong Lim and Vincenzo Mazzaferro and Reiner Wiest and Mar{\'i}a Reig and Andrea Wagner and Luigi Bolondi",
year = "2013",
doi = "10.1016/j.ejca.2013.05.028",
language = "English",
volume = "49",
pages = "3412--3419",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL:
[email protected],
[email protected], INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010",
}